← All organizations
Highest phase reached
Phase 3
Timeline
2020s
- Aug 26, 2020
empagliflozin— Marketing Organization
- Oct 29, 2020
Synteract, Inc.— Acquired
Drugs by trial phase (176 distinct, 173 trials)
Phase 4 (0 own, 3 via acquisition)
Phase 3 (23 own, 17 via acquisition)
Phase 2 (16 own, 34 via acquisition)
Phase 1 (48 own, 29 via acquisition)
Other trials (2 own, 4 via acquisition)
Indications
Studied for
- Acute Lung Injury
- alpha 1-Antitrypsin Deficiency
- Aspergillosis
- Clostridium Infections
- Coronary Disease
- Diabetic Neuropathies
- Dry Eye Syndromes
- Dystonia
- Dystonic Disorders
- Emphysema
- Eunuchism
- Eye Diseases
- Fibromyalgia
- Fibrosis
- Heart Diseases
- Hypertension
- Hypogonadism
- Idiopathic Pulmonary Fibrosis
- Infarction
- Invasive Pulmonary Aspergillosis
- Keratitis
- Keratoconjunctivitis Sicca
- Liver Diseases
- Lung Diseases
- Lung Neoplasms
- Melanoma
- Myocardial Infarction
- Myofascial Pain Syndromes
- Neuralgia
- Opioid-Related Disorders
- Peripheral Nervous System Diseases
- Pulmonary Aspergillosis
- Pulmonary Fibrosis
- Renal Insufficiency
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Respiratory Tract Diseases
- Respiratory Tract Infections
- ST Elevation Myocardial Infarction
- Torticollis
- Vascular Diseases
- Virus Diseases
- Zika Virus Infection
Marketed drugs (2)
Subsidiaries (3 direct, 9 total across the full acquisition tree)
Recent trials (50)
- NCT06965751CollaboratorPhase 1Jun 27, 2025
- NCT06699836CollaboratorPhase 2Feb 28, 2025
- NCT06780254CollaboratorPhase 1Sep 9, 2024
- NCT05805618Lead sponsorEarly Phase 1Jul 1, 2024
- NCT06435039Lead sponsorPhase 1Jun 26, 2024
- NCT06453824OfficialPhase 1May 17, 2024
- NCT06204250CollaboratorPhase 1Feb 27, 2024
- NCT06194864CollaboratorPhase 1Jan 18, 2024
- NCT06170827Lead sponsorPhase 1Dec 19, 2023
- NCT05817812CollaboratorPhase 3Jul 31, 2023
- NCT05896969Lead sponsorPhase 1Apr 27, 2023
- NCT05807971CollaboratorPhase 1Apr 6, 2023
- NCT05668650CollaboratorPhase 3Mar 31, 2023
- NCT05715736Lead sponsorPhase 1Mar 8, 2023
- NCT05721573CollaboratorPhase 2/Phase 3Feb 28, 2023
Details
- Founded
- Raleigh, NC, US Jan 4, 2018
- Last known activity
- Jun 27, 2025